Oxygen Biotherapeutics Inc. (OXBO.OB) Announces Positive Meeting with FDA Regarding Steps toward Traumatic Brain Injury Treatment
Oxygen Biotherapeutics Inc. (OTCBB: OXBO) focuses on commercializing innovative pharmaceuticals and medical devices associated with oxygen therapeutics and continuous substrate monitoring. The company today announced what it refers to as a “fruitful and productive” scientific meeting with the U.S. Food and Drug Administration regarding the company’s Oxycyte in Traumatic Brain Injury (TBI) therapeutic oxygen carrier. According to the press release, the meeting has led the company to the decision it will expand its research plan to include another dose escalation safety and efficacy study for Oxycyte in up to 40 more patients. Oxygen Biotherapeutics will commence patient enrollment in the…